Sign in
Two-Year Results From the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of Neovascular AMD
Robert L. Avery, MD
Updates from the Field
2021
Apples and Oranges: "Real-World" Outcomes Differ From Clinical Trial Outcomes Because "Real-World" Patients Differ From Clinical Trial Patients
Franco M. Recchia, MD
Annual Meeting Talks
Episode 15: Serum VEGF Levels in the IVAN Trial with Dr. Usha Chakravarthy
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018
Category: AMD-Neovascular